Emedgene is the world’s first completely automated genetic interpretation platform. We’re applying the most advanced AI technologies in order to dramatically scale genetic interpretation and discovery. Clinical labs using Emedgene improve dry lab efficiency, reducing time spent on interpretation and reporting, increasing yield, and scaling their genomic interpretation operation. Research organizations using Emedgene accelerate genomic-driven discovery through the application of end-to-end AI, from NLP of publications, through custom machine learning algorithms.
While sequencing is becoming easier, interpreting results is a manual and lengthy research process that forms a bottleneck to the adoption of genetic-based care. Emedgene uses NLP to ‘read’ new genetic publications, and incorporate them into an always up-to-date knowledge base. We then run machine learning discovery algorithms that pinpoint pathogenic variants, for a clear path to clinical decisions. Clinical labs using Emedgene improve dry lab efficiency, reduce time spent on interpretation and reporting, and increase yield without increasing headcount.
Total Funding: $6,000,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2015
Associate Scientist
Palo Alto, California
Sales Coordinator
Palo Alto, California
Strategic Account Manager
Palo Alto, California
DevOps Engineer
Palo Alto, California
Senior Backend Engineer
Palo Alto, California
